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BH3 Mimetic ABT-737 and a Proteasome Inhibitor
Synergistically Kill Melanomas through
Noxa-Dependent Apoptosis
Leslie A. Miller1, Nathaniel B. Goldstein1, Widya U. Johannes1, Christine H. Walton1, Mayumi Fujita1,
David A. Norris1,2,3 and Yiqun G. Shellman1,3
The Bcl-2 family is important in modulating sensitivity to anticancer drugs in many cancers, including
melanomas. The BH3 mimetic ABT-737 is a potent small molecule inhibitor of the anti-apoptotic proteins Bcl-2/
Bcl-XL/Bcl-w. In this report, we examined whether ABT-737 is effective in killing melanoma cells in combination
with the proteasome inhibitor MG-132, and further evaluated the mechanisms of action. Viability,
morphological, and Annexin V apoptosis assays showed that ABT-737 alone exhibited little cytotoxicity, yet it
displayed strong synergistic lethality when combined with MG-132. In addition, the detection of Bax/Bak
activation indicated that the combination treatment synergistically induced mitochondria-mediated apoptosis.
Furthermore, mechanistic analysis revealed that this combination treatment induced expression of the
pro-apoptotic protein Noxa- and caspase-dependent degradation of the anti-apoptotic protein, Mcl-1. Finally,
siRNA-mediated inhibition of Mcl-1 expression significantly increased sensitivity to ABT-737 in these cells, and
knocking down Noxa expression protected the cells from cytotoxicity induced by the combination treatment.
These findings demonstrate that ABT-737 combined with MG-132 synergistically induced Noxa-dependent
mitochondrial-mediated apoptosis. In summary, this study indicates promising therapeutic potential of
targeting anti-apoptotic Bcl-2 family members in treating melanoma, and it validates rational molecular
approaches that target anti-apoptotic defenses when developing cancer treatments.
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INTRODUCTION
Malignant melanoma is largely unresponsive to existing
therapies and has a very poor prognosis (Buzaid, 2004;
Cummins et al., 2006; Gogas et al., 2007). In addition, there
has been little progress over the past 30 years in medical
treatment of this disease. Thus, the paucity of effective treatments
for malignant melanoma is a pressing issue in medicine.
The recent use of proteasome inhibition in clinical practice
to induce apoptosis in cancer has produced interesting results.
However, proteasome inhibition alone is neither complete nor
sustained because of the need to limit secondary toxicity
(Adams, 2004). In addition, pharmacokinetic analyses have
indicated that proteasome inhibitors are rapidly inactivated by
hepatic detoxification (Schwartz and Davidson, 2004). There-
fore, compounds that synergize with proteasome inhibitors to
lower required dosages and/or to minimize the time delay from
proteasome inhibition to the activation of the apoptotic
machinery could have important clinical implications.
Apoptosis is one of the main pathways contributing to the
cytotoxic effects of conventional cancer treatments, and
functional apoptotic pathways are required for the success of
most treatments. During melanoma’s progression, malignant
cells become ‘bullet proof’ against a variety of chemother-
apeutic drugs by exploiting their intrinsic apoptotic defenses
and by reprogramming their proliferation and survival path-
ways (Soengas and Lowe, 2003).
The Bcl-2 family of proteins is crucial in regulating apoptosis
(see review Thomadaki et al., 2006), especially mitochondria-
dependent apoptotic cell death. This family can be divided into
three groups: anti-apoptotic proteins, including proteins such as
Bcl-2, Bcl-XL, Bcl-w, and Mcl-1; multi-domain pro-apoptotic
proteins Bax and Bak; and pro-apoptotic BH3-only proteins,
including Noxa, Bim, Bid, Bad, Bmf, and Bik.
Molecular-targeted therapy holds the promise of providing
new and more effective treatment options with minimal
toxicity (Weinstein and Joe, 2006). Compounds have been
developed to target activated kinases or receptors (Weinstein
and Joe, 2006), but there are also many advantages for
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targeting the defective apoptotic machinery in cancer cells:
(1) Even though different gene mutations exist in different
types of cancers, downstream pathways that include anti-
apoptotic defenses are very similar. (2) Abnormally regulated
apoptotic signaling is one of the hallmarks of cancer. (3)
Finding molecular targets in anti-apoptotic defenses will
provide molecular targets for cancer therapy that differ from
targeting kinases or receptors.
ABT-737 (developed by Abbott Laboratories) is a
potent small molecule inhibitor of the anti-apoptotic proteins
Bcl-2, Bcl-XL, and Bcl-w with an affinity 2–3 orders of
magnitude more potent than any previously reported
compounds (Letai, 2005; Oltersdorf et al., 2005). It acts like
a BH3—only protein to antagonize anti-apoptotic Bcl-2
family members, thereby diminishing their ability to inhibit
apoptosis (Oltersdorf et al., 2005). Many teams have recently
reported the high efficacy of ABT-737 either as a single agent
or as a chemo-potentiator in combination with other
chemotherapeutic agents to treat multiple types of cancers,
including lymphoma, small-cell lung carcinoma, various
leukemias, etc. (Adams et al., 2005; Oltersdorf et al., 2005;
Certo et al., 2006; Konopleva et al., 2006; Shoemaker et al.,
2006; van Delft et al., 2006; Chauhan et al., 2007; Chen
et al., 2007a, b; Kang et al., 2007; Kohl et al., 2007).
In this study, we explored whether ABT-737 is effective
in treating human melanoma cell lines and whether it
potentiates killing of melanoma cells by the proteasome
inhibitor, MG-132. We found that the two drugs acted
synergistically to activate Noxa-dependent mitochondrial-
mediated apoptosis. Mechanistic analysis suggests that this
combination increases pro-apoptotic protein Noxa expres-
sion, neutralizes all main anti-apoptotic Bcl-2 proteins, and
induces accelerated Noxa-mediated synergistic killing.
RESULTS
ABT-737 synergistically killed human melanoma cells when
combined with MG-132
There are important clinical implications for finding com-
pounds that synergize with proteasome inhibitors to lower
the required doses and/or to minimize the time delay from
proteasome inhibition to the activation of apoptotic machin-
ery. We examined the effects of ABT-737 alone or in
combination with MG-132 in treating A375, WM852c and
HS294T human melanoma cells using a tetrazolium com-
pound [3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxy-
phenyl)-2 (4-sulfophenyl)-2H-tetrazolium], inner salt (MTS)
assays and ethidium bromide and acridine orange (EB/AO)
staining. The relative cell viability present in Figure 1 reveals
that ABT-737 alone caused little cytotoxicity in these cells,
but both 1.1 and 3.3 mM ABT-737 significantly increased
killing effects of MG-132. To quantify whether these
combinations had synergistic, additive or antagonistic effects,
we used Calcusyn software to calculate the combination
index (CI) value for each experimental combination with the
data from Figure 1 (Figure S1). We found that the MG-132
and ABT-737 combination treatments displayed strong
synergistic killing for these melanoma cell lines, and similar
results were observed with EB/AO staining (Figure S2).
ABT-737 combined with MG-132 induced apoptosis
synergistically in human melanoma cell lines through the
intrinsic pathway (mitochondria mediated)
We performed additional assays to further examine whether
the combination of ABT-737 and MG-132 induces apoptosis
synergistically in melanoma cells (Figure 2).
First, Figure 2a illustrates bright field microscopic mor-
phology of A375 and WM852c melanoma cells. Compared
with the DMSO control, ABT-737 alone did not affect
the cellular morphology significantly, and MG-132 alone
minimally increased the number of rounded cells, which still
appeared alive. In contrast, the combination treatment
caused almost all cells to detach and appear dead.
Second, Figure 2b presents the results from Annexin V
staining of A375 and WM852c melanoma cells. The
combination of ABT-737 and MG-132 induced many more
apoptotic cells than the sum total of apoptotic cells induced
by either drug alone, demonstrating the synergistic killing
effects of the combination. Statistical analysis indicated
that only the combination treatment increased apoptosis
significantly from DMSO controls in both cell lines.
Third, to further delineate the pathway, we examined
whether these treatments induced Bax/Bak activation (Figure
2c). Bax and Bak are multi-domain pro-apoptotic Bcl-2
family members that are essential for mitochondria-depen-
dent apoptosis (Wei et al., 2001). Bax and/or Bak activation is
associated with conformational changes that can be detected
by specific antibodies, and it is a good indicator of
mitochondria-mediated apoptosis (Griffiths et al., 1999;
Nechushtan et al., 1999). ABT-737 or MG-132 alone induced
activation of Bax/Bak in a small percentage of WM852c
melanoma cells, but the number of Bak/Bax-activated cells
induced by the combination treatment was more than double
the amount of the sum total of positive cells induced by
ABT-737 and MG-132 alone, indicating strong synergism as
opposed to additive effects (Figure 2c). Statistical analysis
indicated that only the combination treatment increased
active Bak/Bax positive cells significantly from DMSO
controls. Similar results were seen with A375 cells (Figure 2c).
Taken together, the synergistic induction of mitochondria-
mediated apoptosis by ABT-737 and MG-132 was demon-
strated by morphology of the treated cells, measurements of
the apoptotic cell populations by Annexin V/propidium
iodide staining, and the detection of Bax/Bak activation.
Combination of ABT-737 and MG-132 induced expression of
the pro-apoptotic protein Noxa- and caspase-dependent
degradation of the anti-apoptotic protein Mcl-1
MG-132 has been reported to induce expression of the pro-
apoptotic protein Noxa, which has been shown to activate
apoptosis through antagonizing Mcl-1 function in melanoma
(Fernandez et al., 2005; Qin et al., 2005). Thus, we
hypothesized that ABT-737 would block the function of
Bcl-2, Bcl-XL, Bcl-w, whereas MG-132 would induce
Noxa production, neutralizing the anti-apoptotic function of
Mcl-1. Thus, ABT-737 and MG-132 together would inhibit all
four anti-apoptotic proteins to synergistically induce
apoptosis.
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To investigate this hypothesis, we examined changes in Bcl-2
family protein expression by Western blot. Only Noxa and
Mcl-1 protein levels had consistent and dramatic changes
induced by either one drug alone and/or the combination
24hours post-treatment (Figure 3a and Figure S3). ABT-737
alone had little effects on most proteins examined, and MG-
132 alone induced both Noxa and Mcl-1 levels substantially
(Figure 3a). The combination treatment increased Noxa
expression to similar levels as MG-132 alone. However,
surprisingly, Mcl-1 expression in cells treated with the drug
combination was reduced to levels similar to cells treated with
vehicle control or ABT-737 alone (Figure 3a).
To examine the unexpected decrease in Mcl-1 expression
in cells treated with the drug combination compared with
increased levels of Mcl-1 in cells treated with MG-132 alone,
we performed time course experiments (WM852c in Figure
3b and A375 in Figure S4). Results showed that Mcl-1 protein
expression was induced by the combination treatment for up
to 6 hours, but it was reduced to endogenous levels at
24 hours. Caspase 3 was activated at 24 hours but not the
earlier time points.
Downregulation of Mcl-1 at the protein level can be
achieved through proteasomal degradation (Cuconati et al.,
2003; Nijhawan et al., 2003; Willis et al., 2005) or caspase-
dependent specific cleavage (Clohessy et al., 2004; Michels
et al., 2004). In our case, we hypothesized that the latter
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Figure 1. Combination of ABT-737 and MG-132 killed human melanoma
cells synergistically. Cells were seeded in 96-well plates 24 hours before
treatment with ABT-737, MG-132, or both drugs at indicated doses. MTS
assays were performed 48hours post-treatment. Averaged media controls for
multiple plates were set as 100% viability; (a) A375 cells, (b) WM852c cells,
and (c) HS294T cells. Independent experiments have been repeated at least
three times, and similar results have been observed.
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Figure 2. Combination of ABT-737 and MG-132 induced mitochondrial-
mediated apoptosis in melanoma cells synergistically. A375 and WM852c
melanoma cells were treated for 24 hours with DMSO control, 1.1 mM ABT-
737 and 0.18mM MG-132, either alone or in combination. Percentage of
apoptotic cells were analyzed using Annexin V staining. (a) Bright Field
microscopy images of A375 and WM852c cells before being detached for
staining. Scale bar¼ 100mM. (b) Average increase±SEM in apoptosis for
treated A375 and WM852c cells. One-way ANOVA demonstrated significant
differences among Annexin Vþ cells for all treatments of A375 (F¼55.9,
Fcrit¼ 4.07, P¼ 1105) and WM852c (F¼ 5.5, Fcrit¼4.07, P¼ 0.02).
However, Tukey’s post hoc analysis for both cell lines indicated that only the
combination treatment significantly increased percentages of Annexin Vþ
cells compared with DMSO controls for both A375 cells (**Po0.01) and
WM852c cells (*Po0.05). (c) Average increase±SEM in Bak/Bax-activated
cells for treated WM852c or A375 cells. One-way ANOVA demonstrated
statistically significant differences among active Bak/Bax positive cells for all
treatments (Bak: F¼ 21.5, Fcrit¼ 4.07, P¼ 3104; Bax: F¼ 54.9,
Fcrit¼ 4.07, P¼ 1105), but only the combination treatment produced
significantly higher active Bak and Bax positive cells than DMSO control cells
(*Po0.05 and **Po0.01). Data summarized three independent experiments.
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scenario is more likely as MG-132 inhibits proteasome
activity. To determine whether our observed Mcl-1 down-
regulation was dependent on caspase activity, we employed
the wide-spectrum general caspase inhibitor zVAD-fmk in
our experiments.
Figure 4a shows that without zVAD-fmk, ABT-737 plus MG-
132 induced Mcl-1 expression at 4 hours, but downregulated
its expression back to endogenous levels at 24hours, as we
observed before. In contrast, at the 24hours time point, zVAD-
fmk dramatically increased Mcl-1 expression in cells treated
with ABT-737 and MG-132 but not in the control-treated cells.
However, the caspase inhibitor did not affect Noxa expression.
Figure 4b also illustrates that at 24hours, the caspase inhibitor
dramatically increased full length Mcl-1 expression in the
combination-treated cells to a level similar to cells treated with
MG-132 alone in A375 cells. Similar results have been
observed in WM852c cells (Figure S5).
Thus, these data suggest that the combination treatment
induced pro-apoptotic protein Noxa expression, and caspase-
dependent anti-apoptotic protein Mcl-1 degradation.
Knocking down Mcl-1 expression increased melanoma’s
sensitivity to ABT-737 and knocking down Noxa expression
protected cells from killing induced by the combination of
ABT-737 and MG-132
As pro-apoptotic Noxa mainly binds to the anti-apoptotic
protein Mcl-1 but not Bcl-2, Bcl-XL, or Bcl-w, the major
function of Noxa in regulating apoptosis is to antagonize
Mcl-1 (Chen et al., 2005; Willis et al., 2005). To further
investigate the biological relevance of our observed Mcl-1
cleavage and Noxa induction, we examined whether knock-
ing down Mcl-1 expression affected sensitivity to ABT-737 in
melanoma cells using RNA interference (Figure 5). Inhibiting
Mcl-1 expression by siMcl-1 alone was not sufficient to
induce cell death. However, when the cells were treated with
ABT-737, blocking Mcl-1 expression (siMcl-1) significantly
increased Annexin Vþ cells, more than fivefold in both
WM852c and A375 cells (Figure 5a). Immunoblot analysis
indicated that siMcl-1 inhibited Mcl-1 expression by B70%
in both control or ABT-737 treated cells (Figure 5b). These
results demonstrate that Mcl-1 mediates resistance to ABT-
737, and this suggests that in the combination treatment, MG-
132 potentiates ABT-737’s ability to induce cell death by
upregulating Noxa expression to antagonize Mcl-1.
We then investigated whether inhibiting Noxa expression
affected the synergistic killing induced by the combination
drug treatment (Figure 6). When WM852c cells were treated
with the combination of ABT-737 and MG-132, blocking
Noxa expression by siNOXA significantly decreased total
Annexin Vþ cells by almost 50% (from 64.8±1.9 to
A375
737 132737 132
WM852c
Treatment
McI-1
Noxa
Tubulin
(40 kDa)
(6 kDa)
McI-1
Time-point (hours) 2
− + + + +− − −
4 6 24
Combination
treatment
Noxa
Tubulin
(19 & 17 kDa)
Caspase 3
(35 kDa)
Cleaved
(40 kDa)
(6 kDa)
DMSO DMSO ABT-  MG- Comb.ABT- MG- Comb.
Figure 3. The effects of combination treatment with ABT-737 and MG-132
on Noxa and Mcl-1 protein expression. (a) Western blot: A375 or WM852c
cells were treated in the same way as in Figure 2, and lysates were prepared
24hours post-treatment before being subjected to western blot analysis. (b)
Time course experiments of WM852c. Cells were treated with either vehicle
control (DMSO) or the combination of 1.1 mM ABT-737 (ABT) and 0.18mM
MG-132 (MG), and lysates were prepared at indicated time points post-
treatment before being subjected to western blot analysis.
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Figure 4. Caspase inhibitor blocked downregulation of Mcl-1 protein
expression induced by ABT-737 and MG-132 combination treatment. (a)
Western blots: A375 cells were treated with either vehicle control (DMSO) or
the combination of 1.1mM ABT-737 (ABT) and 0.18mM MG-132 (MG). The
general caspase inhibitor zVAD-fmk was used at 30 mM at the same time that
other drugs were added. Lysates were prepared at either 4 or 24 hours post-
treatment. (b) Western blot: A375 cells were treated with either DMSO,
1.1mM ABT-737 (1.1 ABT) and 0.18 mM MG-132 (0.18 MG) or the
combination of 1.1 mM ABT-737 and 0.18mM (Combo). Thirty micromolar
zVAD-fmk was added to the indicated cells at the same time of other
treatments, and lysates were prepared 24 hours post-treatment.
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35.0±1.2%; analyses of variance (ANOVA), P¼0.0002). In
addition, immunoblot analysis indicated that siNOXA in-
hibited Noxa induction by B50% under the combination
treatment condition (Figure 6b). These results suggest that
Noxa is a major mediator of apoptosis induced by the
combination drug treatment.
Take together, Figures 5 and 6 suggest that Mcl-1 mediates
resistance to ABT-737, and the combination treatment of
MG-132 and ABT-737 antagonizes Mcl-1 through increased
Noxa expression and caspase-dependent Mcl-1 cleavage.
These observations explain the potent synergy observed for
the combination treatment.
DISCUSSION
Malignant melanoma is a devastating disease as it metasta-
sizes early and is highly resistant to all conventional
treatments. This study investigates whether the strategies that
combat anti-apoptotic defenses, such as the use of the small
molecule inhibitor ABT-737, might be synergistic with
proteasome inhibitors for treating melanoma. By examining
multiple parameters of cell viability and apoptosis activation,
Figures 1 and 2, Figures S1 and S2 strongly demonstrated that
ABT-737 and MG-132 synergistically induce apoptosis in
melanoma cells. In addition, active Bak/Bax staining con-
firmed that co-treatment of ABT-737 and MG-132 induced
apoptosis through the intrinsic pathway (Figures 2c and
Figure S3). Thus, these data reveal the strong synergy
between ABT-737 and MG-132 in killing melanoma cells
through mitochondria-mediated apoptosis, and they validate
targeting melanoma’s anti-apoptotic defenses as a rational
molecular approach to therapy.
These results are consistent with a recent report that also
showed high efficacy in treating melanoma cells by combin-
ing a proteasome inhibitor (bortezomib) with the natural
product ()-gossypol, a different inhibitor of the anti-
apoptotic proteins Mcl-1/Bcl-2/Bcl-XL (Wolter et al., 2007).
It has been shown that the BH3-only pro-apoptotic protein
Bad binds tightly to the anti-apoptotic proteins Bcl-2, Bcl-XL,
and Bcl-w, but not to Mcl-1, whereas Noxa bind to Mcl-1 and
A1 (Chen et al., 2005; Willis et al., 2005). In accord with their
complementary binding, Bad and Noxa together neutralize
four major anti-apoptotic proteins and cooperate to induce
potent killing (Chen et al., 2005; Willis et al., 2005).
ABT-737 is a mimetic of Bad, as it binds tightly to Bcl-2/
Bcl-XL/Bcl-w and antagonizes their anti-apoptotic function
(Oltersdorf et al., 2005). Just as Bad does, ABT-737 has been
shown to induce apoptosis synergistically with overexpressed
Noxa (van Delft et al., 2006). In addition, high expression of
Mcl-1 (Noxa’s anti-apoptotic counterpart) is a critical factor
for cellular resistance to ABT-737, and resistant cells can be
sensitized by various approaches that downregulate, desta-
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Figure 5. Knocking down Mcl-1 expression increased melanoma cell
sensitivity to ABT-737. Melanoma cells were transiently transfected with siRNA
targeting human Mcl-1 (siMcl-1) or the nontargeting control pool (siControl).
Cells were then cultured for 24hours followed by a treatment with either DMSO
or 3.3mM ABT-737 for an additional 24hours. (a) Annexin V apoptosis assay. For
cells treated with ABT-737, one-way ANOVA demonstrated significantly higher
numbers of Annexin Vþ cells for siMcl-1 transfectants compared with siControl
transfectants (**: WM852c, F¼1049.1, Fcrit¼7.7, P¼5.4 106; ##: A375,
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Figure 6. Blocking Noxa induction rescued cells from synergistic killing by
the combination of MG-132 and ABT-737. WM852c melanoma cells were
transiently transfected with siRNA targeting human Noxa (siNOXA) or the non-
targeting control pool (siControl). Cells were then cultured for 30hours followed
by a treatment with either DMSO or the combination of 1.1mM ABT-737 and
0.18mM MG-132 for 18hours. (a) Annexin V apoptosis assay. For cells treated
with the combination, one-way ANOVA demonstrated significantly lower
numbers of Annexin Vþ cells for siNoxa transfectants compared with siControl
transfectants (*: ANOVA, F¼ 171.6, Fcrit¼7.7, P¼ 0.0002). Results represent
percentages±SEM for three independent experiments and (b) immunoblot.
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bilize, or inactivate Mcl-1 (Konopleva et al., 2006; van Delft
et al., 2006; Chen et al., 2007a, b). We found that knocking
down Mcl-1 expression significantly increased melanoma
cell sensitivity to ABT-737 (Figure 5), indicating that Mcl-1 is
the main barrier for ABT-737-induced cell death.
In melanoma, proteasome inhibitors such as MG-132 and
bortezomib have been reported to induce high levels of Noxa
expression and lead to Noxa-mediated apoptosis (Fernandez
et al., 2005; Qin et al., 2005). We hypothesized that ABT-737
would be synergistic with proteasome inhibitor such as MG-
132 in killing melanoma cells, as ABT-737 blocks the
function of Bcl-2, Bcl-XL, Bcl-w, whereas MG-132 would
induce Noxa production, neutralizing the anti-apoptotic
function of Mcl-1. Thus, ABT-737 and MG-132 together
would inhibit four major anti-apoptotic proteins to synergis-
tically induce apoptosis.
We found that the combination of ABT-737 and MG-132
indeed induced high levels of Noxa expression, similar to
MG-132 treatment alone (Figures 3 and Figure S4a). We also
demonstrated that the combination induced Noxa-dependent
apoptosis (Figure 6), even though Noxa induction alone was
not sufficient to induce apoptosis effectively in these cells
(see MG-132 treatment alone in Figures 1 and 2). Thus, one
of the mechanisms for potent killing synergy between ABT-
737 and MG-132 is that the combination acts similarly to
overexpressing Bad plus Noxa. As a result, the combination
treatment effectively neutralizes all four main anti-apoptotic
proteins, therefore promoting cooperation to induce potent
killing in melanoma.
Interestingly, proteasome inhibitors also have been reported
to induce accumulation of the anti-apoptotic protein Mcl-1
(Fernandez et al., 2005; Qin et al., 2005), and reducing Mcl-1
levels (using siRNA, UV light, or fludarabine) synergizes in
causing proteasome-inhibitor-induced cell death in melanoma
cells (Fernandez et al., 2005; Qin et al., 2005; Gomez-Bougie
et al., 2007). Even partial downregulation of Mcl-1 causes a
two-fold increase in proteasome-inhibitor-induced melanoma
killing (Qin et al., 2006), and more efficient reduction of Mcl-1
expression dramatically increases and accelerates bortezomib-
induced cell death (Wolter et al., 2007).
Although we also observed substantial Mcl-1 accumula-
tion up to at least 24 hours in cells treated with MG-132 alone
and at early time points of combination treatment, full length
Mcl-1 was quickly degraded in the combination treatment at
24 hours (Figures 3 and Figure S4). This rapid destruction of
Mcl-1 might also contribute to potent synergy; likely because
ABT-737 plus MG-132 simultaneously triggers Noxa produc-
tion (by MG-132) and reduces Mcl-1 levels (by ABT-737 plus
MG-132).
Rapid degradation of Mcl-1 can be induced by certain
cytotoxic triggers, including UV irradiation (Nijhawan et al.,
2003; Willis et al., 2005), DNA damage by viral infection
(Cuconati et al., 2003) and detachment (Woods et al., 2007).
Further, destruction of Mcl-1 is essential for apoptosis
induced by these stimuli (Cuconati et al., 2003; Nijhawan
et al., 2003; Willis et al., 2005; Woods et al., 2007), and
elimination of Mcl-1 may help to ensure irreversible
commitment to apoptosis.
In our case, the combination of ABT-737 and MG-132
induced Mcl-1 degradation swiftly in melanoma cells, which
may be another reason for the potent killing synergy seen in
the combination of these two compounds. This rapid
destruction of Mcl-1 might help overcome cellular resistance
to both MG-132 and ABT-737. As shown in Figure 4, the wide-
spectrum caspase inhibitor zVAD-fmk almost completely
blocked Mcl-1 degradation induced by co-treatment with
ABT-737 and MG-132. This demonstrates that Mcl-1 degrada-
tion in the combination treatment is mainly caspase-depen-
dent, although this might only be a by-product of the apoptotic
cascade. However, studies have shown that caspase-depen-
dent Mcl-1 cleavage can be induced by various stimuli,
including the proteasome inhibitor bortezomib, for example,
in multiple myeloma (Clohessy et al., 2004; Michels et al.,
2004; Gomez-Bougie et al., 2007). Further, caspase-depen-
dent Mcl-1 cleavage has been shown not only to abrogate
Mcl-1’s anti-apoptotic function, but also to generate pro-
apoptotic Mcl-1-truncated proteins which enhance the death
signal (Clohessy et al., 2004; Michels et al., 2004). Moreover,
a recent study demonstrated that cleavage-resistant Mcl-1
potently inhibits mitochondrial-mediated apoptosis (Chen
et al., 2007a, b). Thus, we propose that caspase-dependent
Mcl-1 cleavage is also a part of a positive feedback loop in our
study, which accelerates and synergizes the killing effects of
ABT-737 combined with MG-132 in treating melanoma.
Figure 7 summarizes our hypothesis describing the mechan-
isms of potent synergy between ABT-737 and MG-132 in
melanoma. Under normal conditions, cells are kept in check by
anti-apoptotic proteins such as Bcl-2, Bcl-XL, Bcl-w, and Mcl-1
(apoptotic inhibitors in Figure 7). On co-treatment of ABT-737
and MG-132, the Bad mimetic ABT-737 initially blocks the
function of Bcl-2, Bcl-XL, and Bcl-w, whereas MG-132 induces
Noxa production, which in turn, neutralizes the anti-apoptotic
function of Mcl-1. Thus, ABT-737 and MG-132 together inhibit
all four anti-apoptotic proteins, tilting the balance toward Bax/
Bak activation and inducing Noxa-dependent apoptosis.
Secondarily, when a slight amount of caspase is activated,
Mcl-1 is cleaved. This eliminates the full length Mcl-1
MG132ABT-737
Apoptotic inhibitors:
BcI-2, BcI-XL, BcI-w McI-1
Apoptotic inhibitor:
Positive feedback
by caspase-
dependent McI-1
cleavage
Apoptosis
Caspases activation
Oligomerization
Bak, Bax
Noxa ↑↑
Figure 7. Proposed model for the synergistic mechanism of ABT-737 and
MG-132 combination treatment.
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(induced by MG-132) quickly, and generates pro-apoptotic
Mcl-1 cleavage products that synergize even further in the
death signal. Therefore, caspase-dependent Mcl-1 cleavage
produces a positive feedback signal for apoptosis induced by
the combination of ABT-737 and MG-132.
In conclusion, this study demonstrates that ABT-737
lowers the apoptotic threshold for the proteasome inhibitor
MG-132 in melanoma to induce Noxa-dependent mitochon-
drial-mediated apoptosis very effectively in melanoma cells.
These effects are probably due to both drugs’ combined
ability to neutralize multiple anti-apoptotic proteins and
induce caspase-dependent Mcl-1 cleavage to create a
positive feedback death signal. These results not only provide
scientific basis for further animal and clinical studies to
evaluate the efficacy of this combination in treating
melanomas, but also implicate the importance of testing
additional drug combinations that simultaneously target
multiple anti-apoptotic defenses.
MATERIALS AND METHODS
Cell lines and culture conditions
A375, an advanced vertical growth phase human melanoma cell
line, was obtained from ATCC (Manassas, VA). WM852c and
HS294T, two metastatic human melanoma cell lines, were kindly
provided by Dr. Meenhard Herlyn (Wistar Institute, Philadelphia,
PA). Cells were maintained in RPMI1640 (Invitrogen, Grand Island,
NY) with 10% fetal bovine serum (Gemini Bio-Products Inc., West
Sacramento, CA). A375 has a BRAFV600E mutation and no common
mutations in NRAS (exon 1 or 2), and WM852c has an NRASQ61R
mutation but no BRAF mutation (exon 11 or 15).
Reagents
MG-132 and z-VAD-FMK were purchased from EMD Biosciences
(San Diego, CA) and R&D Systems (Minneapolis, MN), respectively.
ABT-737 was kindly provided by Abbott Laboratories (Abbott Park, IL).
Cell titer 96 aqueous one solution cell proliferation assay for
quantification of cell viability (MTS assay)
The reagents were obtained from Promega (Madison, WI), and pro-
cedures were followed as previously described (Shellman et al., 2005).
Measurement of apoptosis using Annexin V staining
The Annexin V–fluorescein isothiocyanate Apoptosis Detection Kit
(BD Biosciences, San Jose, CA) was used according to the
manufacturer’s protocol. Cells were analyzed by flow cytometry
using a Beckman Coulter FC500 with CXP software (Hialeah, FL) in
the University of Colorado Cancer Center Flow Cytometry Core.
Immunoblot
Cells, both floating and adherent, were harvested with 1 Laemmli
sample buffer (Bio-Rad, Hercules, CA). Samples were used in the
standard western blot analysis protocol as described previously (Ruth
et al., 2006). Blots were developed with horseradish peroxidase
substrate (West Pico or Femto solutions, Pierce, Rockford, IL) for
5minutes at room temperature, and analyzed using a Chemi-doc
chemiluminescence detector (Bio-Rad). The following antibodies
were used at the suggested dilution from the manufacturers: caspase
3, poly (ADP-ribose) polymerase, Bax, and tubulin a/b from Cell
Signaling Technology (Danvers, MA), Noxa, anti-actin mouse
monoclonal antibody and horseradish peroxidase-conjugated goat
anti-mouse immunoglobulin M from EMD Biosciences Inc., Bad,
Bcl-x, Mcl-1, and horseradish peroxidase-conjugated goat anti-
rabbit immunoglobulin G from BD Biosciences, Bim from Chemicon
(Temecula, CA), Bcl-2 from Dako (Glostrup, Denmark), and horse-
radish peroxidase-conjugated goat anti-mouse IgG from Jackson
Immuno-Research (West Grove, PA).
Measurement of mitochondrial-mediated apoptosis with active
Bax/Bak staining
Cells were stained with a protocol modified as previously described
(Qin et al., 2006). Cells were detached and fixed in 2%
formaldehyde (PolySciences Inc., Warrington, PA) (10minutes,
room temperature), and then washed with FACS buffer (phosphate-
buffered saline solution containing 5% fetal bovine serum and
0.02% sodium azide) three times. Cells were permeabilized
briefly with 0.03% saponin/FACS buffer before incubated with
primary antibody in the same buffer (30minutes, room temperature).
Mouse anti-active-human-Bax antibody (BD Pharmingen,
San Jose, CA) at a 1:100 dilution, and mouse anti-active-human-
Bak antibody (EMD Biosciences) was used at a 1:250 dilution.
Fluorescein isothiocyanate-conjugated goat anti-mouse antibody
(Jackson ImmunoResearch, West Grove, PA) were used in 0.3%
saponin/FACS buffer at a 1:750 dilution (30minutes in the dark,
room temperature). FACS buffer was used as the washing solution for
three times after incubation with each antibody. Stained cells were
analyzed by flow cytometry in the University of Colorado Cancer
Center Flow Cytometry Core. Average percent increase in Bak/Bax
activated cell was calculated as the percent increase of active Bakþ /
Baxþ cells in treated conditions over the DMSO controls.
RNA interference
ON-TARGETplus SMARTpools of siRNA were purchased from
Dharmacon Inc. (Lafayette, CO), targeting human Noxa (PMAIP1,
NM_021127), human Mcl-1 (MCL1, NM_182763), and the non-
targeting control pool. siRNA was introduced into cells using an
Amaxa Nucleofector II device (Amaxa Inc., Gaithersburg, MD). One
million cells and 2.5 mM siRNA were used with Amaxa’s Reagent V
and program X-005 for each reaction.
Cells were nucleofected with indicated siRNA and cultured for
indicated amount of time. Then all medium was removed and fresh
medium containing indicated compounds for indicated time before
the cells were harvested for analysis.
Statistical analysis
Statistical analyses were performed similarly for both Annexin V
staining and active Bak/Bax staining. One-way ANOVA were
performed to compare group means, and Tukey’s post hoc tests
were used to compare treated samples to DMSO controls.
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Figure S5. Caspase inhibitor zVAD-fmk blocked downregulation of Mcl-1
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